Literature DB >> 16764746

Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study.

Baudewijntje P C Kreukels1, Sanne B Schagen, K Richard Ridderinkhof, Willem Boogerd, Hans L Hamburger, Martin J Muller, Frits S A M van Dam.   

Abstract

BACKGROUND: The mechanisms underlying cognitive deficits found in a number of patients with breast cancer treated with adjuvant chemotherapy are still unclear. In the current study, we used a combination of measures of brain electric activity and cognitive performance during information processing to elucidate the origin of these cognitive deficits. PATIENTS AND METHODS: Twenty-nine patients at high risk with breast cancer treated with adjuvant conventional-dose cyclophosphamide/epirubicin/5-fluorouracil or adjuvant high-dose cyclophosphamide/thiotepa/carboplatin were compared with 23 patients with stage I breast cancer not treated with chemotherapy approximately 4 years after completion of treatment. We studied reaction times and the amplitudes and latencies of the P3, an electrophysiologic index of information processing, in a task with different conditions related to input, central, and output processing of information.
RESULTS: The amplitude of the P3 component was significantly reduced in patients with breast cancer treated with high-dose cyclophosphamide/thiotepa/carboplatin compared with patients with breast cancer not treated with chemotherapy. We observed no significant differences in reaction times and P3 latency between the treatment groups.
CONCLUSION: Our data show electrophysiologic alterations in patients with breast cancer treated with high-dose chemotherapy 4 years after completion of treatment. The observed P3 reduction might be a result of suboptimal phasic cortical arousal and problems with the allocation of processing resources in these patients.

Entities:  

Mesh:

Year:  2006        PMID: 16764746     DOI: 10.3816/CBC.2006.n.015

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  18 in total

Review 1.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

Review 2.  Clearing the air: a review of our current understanding of "chemo fog".

Authors:  Erin O'Farrell; Joyce MacKenzie; Barbara Collins
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

3.  Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment.

Authors:  Keiko Kurita; Beth E Meyerowitz; Per Hall; Margaret Gatz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-08-22       Impact factor: 6.053

4.  Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.

Authors:  Michiel B de Ruiter; Liesbeth Reneman; Willem Boogerd; Dick J Veltman; Frits S A M van Dam; Aart J Nederveen; Epie Boven; Sanne B Schagen
Journal:  Hum Brain Mapp       Date:  2010-07-28       Impact factor: 5.038

Review 5.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

6.  Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.

Authors:  Victoria J Bray; Haryana M Dhillon; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2018-05-04       Impact factor: 4.442

Review 7.  Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment.

Authors:  Christine D Craig; Bradley J Monk; John H Farley; Dana M Chase
Journal:  Support Care Cancer       Date:  2013-11-10       Impact factor: 3.603

8.  Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study.

Authors:  Carole Scherling; Barbara Collins; Joyce Mackenzie; Catherine Bielajew; Andra Smith
Journal:  Front Hum Neurosci       Date:  2011-11-01       Impact factor: 3.169

Review 9.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

Review 10.  Opening up the window into "chemobrain": a neuroimaging review.

Authors:  Carole S Scherling; Andra Smith
Journal:  Sensors (Basel)       Date:  2013-03-06       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.